FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1594-1602 November 30, 2000 Number 22 Next

	Full Text PDF Editorial by Klippel, J. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Neutralization of tumor necrosis factor (TNF-) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.

Methods We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-, in intravenous doses of 3 or 10 mg per kilogram of body weight every 4 or 8 weeks in combination with oral methotrexate for 54 weeks. We assessed clinical responses with use of the criteria of the American College of Rheumatology, the quality of life with a health-status questionnaire, and the effect on joint damage radiographically.

Results The combination of infliximab and methotrexate was well tolerated and resulted in a sustained reduction in the symptoms and signs of rheumatoid arthritis that was significantly greater than the reduction associated with methotrexate therapy alone (clinical response, 51.8 percent vs. 17.0 percent; P<0.001). The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone. Radiographic evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiographic score, 7.0 vs. 0.6; P<0.001). Radiographic evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clinical response.

Conclusions In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clinical benefit and halted the progression of joint damage.

Source Information

From the University of Texas Southwestern Medical Center at Dallas, Dallas (P.E.L.); University Hospital Maastricht, Maastricht, the Netherlands (D.M.F.M.H.); Duke University Medical Center, Durham, N.C. (E.W.S.), Virginia Mason Research Center, Seattle (D.E.F.); the University of Leiden, Leiden, the Netherlands (F.C.B.); the Institute for Clinical Immunology, Erlangen, Germany (J.R.K.); the University of Vienna, Vienna, Austria (J.S.S.); the University of California at San Diego, San Diego (M.W.); the Research School of Medicine, University of Leeds, Leeds, United Kingdom (P.E.); the Kennedy Institute of Rheumatology and the Imperial College School of Medicine at Charing Cross Hospital, London (M.F., R.N.M.); and Centocor, Malvern, Pa. (G.R.H.).

Address reprint requests to Dr. Lipsky at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bldg. 10, Rm. 9N228, Bethesda, MD 20892-1820, or at lipskyp{at}mail.nih.gov.

Full Text of this Article

This article has been cited by other articles:

• Isenberg, D, Gordon, C, Merrill, J, Urowitz, M (2008). New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution. Lupus 17: 967-970  
• Kapetanovic, M C, Lindqvist, E, Saxne, T, Eberhardt, K (2008). Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis 67: 1412-1416 [Abstract] [Full Text]  
• Buch, M. H., Reece, R. J., Quinn, M. A., English, A., Cunnane, G., Henshaw, K., Bingham, S. J., Bejarano, V., Isaacs, J., Emery, P. (2008). The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 47: 1469-1475 [Abstract] [Full Text]  
• Conte, F. d. P., Barja-Fidalgo, C., Verri, W. A. Jr., Cunha, F. Q., Rae, G. A., Penido, C., Henriques, M. d. G. M. O. (2008). Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-{alpha}, and CXCL-1. J. Leukoc. Biol. 84: 652-660 [Abstract] [Full Text]  
• Paltiel, M., Gober, L. M., Deng, A., Mikdashi, J., Alexeeva, I., Saini, S. S., Gaspari, A. A. (2008). Immediate Type I Hypersensitivity Response Implicated in Worsening Injection Site Reactions to Adalimumab. Arch Dermatol 144: 1190-1194 [Abstract] [Full Text]  
• Silva, L., Fernandez-Castro, M., Andreu, J.-L. (2008). Repairing erosions in rheumatoid arthritis. A realistic goal. Rheumatology (Oxford) 47: 1432-1433 [Full Text]  
• van Riel, P L C M, Freundlich, B, MacPeek, D, Pedersen, R, Foehl, J R, Singh, A, on behalf of ADORE study investigators, (2008). Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 67: 1104-1110 [Abstract] [Full Text]  
• La, D T, Collins, C E, Yang, H-T, Migone, T-S, Stohl, W (2008). B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor {alpha} antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 67: 1132-1138 [Abstract] [Full Text]  
• Gerloni, V, Pontikaki, I, Gattinara, M, Fantini, F (2008). Focus on adverse events of tumour necrosis factor {alpha} blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 67: 1145-1152 [Abstract] [Full Text]  
• Schiff, M, Keiserman, M, Codding, C, Songcharoen, S, Berman, A, Nayiager, S, Saldate, C, Li, T, Aranda, R, Becker, J-C, Lin, C, Cornet, P L N, Dougados, M (2008). Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096-1103 [Abstract] [Full Text]  
• Hyrich, K. L., Lunt, M., Dixon, W. G., Watson, K. D., Symmons, D. P. M., on behalf of the BSR Biologics Register, (2008). Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 47: 1000-1005 [Abstract] [Full Text]  
• Sekiguchi, N., Kawauchi, S., Furuya, T., Inaba, N., Matsuda, K., Ando, S., Ogasawara, M., Aburatani, H., Kameda, H., Amano, K., Abe, T., Ito, S., Takeuchi, T. (2008). Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-{alpha} monoclonal antibody, infliximab. Rheumatology (Oxford) 47: 780-788 [Abstract] [Full Text]  
• Coates, L. C., Cawkwell, L. S., Ng, N. W. F., Bennett, A. N., Bryer, D. J., Fraser, A. D., Emery, P., Marzo-Ortega, H. (2008). Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47: 897-900 [Abstract] [Full Text]  
• Coates, L C, Cawkwell, L S, Ng, N W F, Bennett, A N, Bryer, D J, Fraser, A D, Emery, P, Marzo-Ortega, H (2008). Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 67: 717-719 [Abstract] [Full Text]  
• Matsumoto, T., Kaneko, T., Seto, M., Wada, H., Kobayashi, T., Nakatani, K., Tonomura, H., Tono, Y., Ohyabu, M., Nobori, T., Shiku, H., Sudo, A., Uchida, A., Stearns Kurosawa, D. J., Kurosawa, S. (2008). The Membrane Proteinase 3 Expression on Neutrophils Was Downregulated After Treatment With Infliximab in Patients With Rheumatoid Arthritis. CLIN APPL THROMB HEMOST 14: 186-192 [Abstract]  
• Genovese, M C, Schiff, M, Luggen, M, Becker, J-C, Aranda, R, Teng, J, Li, T, Schmidely, N, Le Bars, M, Dougados, M (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 547-554 [Abstract] [Full Text]  
• Emery, P., McInnes, I. B., van Vollenhoven, R., Kraan, M. C. (2008). Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47: 392-398 [Abstract] [Full Text]  
• Karlsson, J. A., Kristensen, L. E., Kapetanovic, M. C., Gulfe, A., Saxne, T., Geborek, P. (2008). Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 507-513 [Abstract] [Full Text]  
• Kristensen, L. E., Kapetanovic, M. C., Gulfe, A., Soderlin, M., Saxne, T., Geborek, P. (2008). Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 495-499 [Abstract] [Full Text]  
• Okazaki, K., Kondo, M., Kato, M., Kakinuma, R., Nishida, A., Noda, M., Taniguchi, K., Kimura, H. (2008). Serum Cytokine and Chemokine Profiles in Neonates With Meconium Aspiration Syndrome. Pediatrics 121: e748-e753 [Abstract] [Full Text]  
• Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., Maclean, R., Yuan, Y., Oster, G. (2008). Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 47: 535-541 [Abstract] [Full Text]  
• Flossmann, O, Bacon, P, de Groot, K, Jayne, D, Rasmussen, N, Seo, P, Westman, K, Luqmani, R (2008). Development of comprehensive disease assessment in systemic vasculitis. Postgrad. Med. J. 84: 143-152 [Abstract] [Full Text]  
• Aletaha, D, Strand, V, Smolen, J S, Ward, M M (2008). Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 67: 238-243 [Abstract] [Full Text]  
• Takeuchi, T, Tatsuki, Y, Nogami, Y, Ishiguro, N, Tanaka, Y, Yamanaka, H, Kamatani, N, Harigai, M, Ryu, J, Inoue, K, Kondo, H, Inokuma, S, Ochi, T, Koike, T (2008). Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194 [Abstract] [Full Text]  
• van der Heijde, D, Burmester, G, Melo-Gomes, J, Codreanu, C, Mola, E M., Pedersen, R, Freundlich, B, Chang, D J, for the Etanercept Study 400 Investigators, (2008). The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 67: 182-188 [Abstract] [Full Text]  
• Phelan, J. D., Orekov, T., Finkelman, F. D. (2008). Cutting Edge: Mechanism of Enhancement of In Vivo Cytokine Effects by Anti-Cytokine Monoclonal Antibodies. J. Immunol. 180: 44-48 [Abstract] [Full Text]  
• Soderlin, M K, Geborek, P (2008). Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 67: 37-42 [Abstract] [Full Text]  
• Kievit, W, Fransen, J, Oerlemans, A J M, Kuper, H H, van der Laar, M A F J, de Rooij, D J R A M, De Gendt, C M A, Ronday, K H, Jansen, T L, van Oijen, P C M, Brus, H L M, Adang, E M, van Riel, P L C M (2007). The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66: 1473-1478 [Abstract] [Full Text]  
• Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E., van Vollenhoven, R. (2007). Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1462-1466 [Abstract] [Full Text]  
• Verstappen, S M M, Jacobs, J W G, van der Veen, M J, Heurkens, A H M, Schenk, Y, ter Borg, E J, Blaauw, A A M, Bijlsma, J W J, on the behalf of the Utrecht Rheumatoid Arthritis, (2007). Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Vasilopoulos, Y, Gkretsi, V, Armaka, M, Aidinis, V, Kollias, G (2007). Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis. Ann Rheum Dis 66: iii23-iii28 [Abstract] [Full Text]  
• Askling, J., Fored, C M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Coster, L., Geborek, P., Jacobsson, L. T, Lindblad, S., Lysholm, J., Rantapaa-Dahlqvist, S., Saxne, T., van Vollenhoven, R. F, Klareskog, L. (2007). Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66: 1339-1344 [Abstract] [Full Text]  
• van der Kooij, S. M, de Vries-Bouwstra, J. K, Goekoop-Ruiterman, Y. P M, van Zeben, D., Kerstens, P. J S M, Gerards, A. H, van Groenendael, J. H L M, Hazes, J. M W, Breedveld, F. C, Allaart, C. F, Dijkmans, B. A C (2007). Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66: 1356-1362 [Abstract] [Full Text]  
• Nugent, K., Diri, E., Tello, W., Ratnoff, W.D. (2007). Letter To the Editor: Infliximab-induced SLE-like syndrome involving the lung and pleura. Lupus 16: 764-766  
• Zhong, X.-Y., von Muhlenen, I., Li, Y., Kang, A., Gupta, A. K., Tyndall, A., Holzgreve, W., Hahn, S., Hasler, P. (2007). Increased Concentrations of Antibody-Bound Circulatory Cell-Free DNA in Rheumatoid Arthritis. Clin. Chem. 53: 1609-1614 [Abstract] [Full Text]  
• Biswal, S., Resnick, D. L., Hoffman, J. M., Gambhir, S. S. (2007). Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice. Radiology 244: 651-671 [Abstract] [Full Text]  
• Adriaansen, J, Khoury, M, de Cortie, C J, Fallaux, F J, Bigey, P, Scherman, D, Gould, D J, Chernajovsky, Y, Apparailly, F, Jorgensen, C, Vervoordeldonk, M J B M, Tak, P P (2007). Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 66: 1143-1150 [Abstract] [Full Text]  
• Hjardem, E., Ostergaard, M., Podenphant, J., Tarp, U., Andersen, L. S., Bing, J., Peen, E., Lindegaard, H. M., Ringsdal, V. S., Rodgaard, A., Skot, J., Hansen, A., Mogensen, H. H., Unkerskov, J., Hetland, M. L. (2007). Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 66: 1184-1189 [Abstract] [Full Text]  
• Rahman, M. U, Strusberg, I., Geusens, P., Berman, A., Yocum, D., Baker, D., Wagner, C., Han, J., Westhovens, R. (2007). Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1233-1238 [Abstract] [Full Text]  
• van der Pouw Kraan, T C T M, Wijbrandts, C A, van Baarsen, L G M, Voskuyl, A E, Rustenburg, F, Baggen, J M, Ibrahim, S M, Fero, M, Dijkmans, B A C, Tak, P P, Verweij, C L (2007). Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66: 1008-1014 [Abstract] [Full Text]  
• Wittkowski, H., Foell, D., Klint, E. a., Rycke, L. D., Keyser, F. D., Frosch, M., Ulfgren, A.-K., Roth, J. (2007). Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis 66: 1020-1025 [Abstract] [Full Text]  
• Schoels, M, Kapral, T, Stamm, T, Smolen, J S, Aletaha, D (2007). Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis 66: 1059-1065 [Abstract] [Full Text]  
• Fujita, S., Saika, S., Kao, W. W.-Y., Fujita, K., Miyamoto, T., Ikeda, K., Nakajima, Y., Ohnishi, Y. (2007). Endogenous TNF{alpha} Suppression of Neovascularization in Corneal Stroma in Mice. IOVS 48: 3051-3055 [Abstract] [Full Text]  
• Furst, D. E, Gaylis, N., Bray, V., Olech, E., Yocum, D., Ritter, J., Weisman, M., Wallace, D. J, Crues, J., Khanna, D., Eckel, G., Yeilding, N., Callegari, P., Visvanathan, S., Rojas, J., Hegedus, R., George, L., Mamun, K., Gilmer, K., Troum, O. (2007). Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66: 893-899 [Abstract] [Full Text]  
• Buch, M. H., Bingham, S. J., Bryer, D., Emery, P. (2007). Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 46: 1153-1156 [Abstract] [Full Text]  
• Lipsky, P. E. (2007). Why Does Rheumatoid Arthritis Involve the Joints?. NEJM 356: 2419-2420 [Full Text]  
• Schett, G., Landewe, R., van der Heijde, D. (2007). Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?. Ann Rheum Dis 66: 709-711 [Full Text]  
• Jois, R. N., Masding, A., Somerville, M., Gaffney, K., Scott, D. G. I. (2007). Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology (Oxford) 46: 980-982 [Abstract] [Full Text]  
• Rennard, S. I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., Mahler, D., Saadeh, C., Siler, T., Snell, P., Korenblat, P., Smith, W., Kaye, M., Mandel, M., Andrews, C., Prabhu, R., Donohue, J. F., Watt, R., Lo, K. H., Schlenker-Herceg, R., Barnathan, E. S., Murray, J., on behalf of the COPD Investigators, (2007). The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 175: 926-934 [Abstract] [Full Text]  
• Jacobsson, L. T H, Turesson, C., Nilsson, J.-A., Petersson, I. F, Lindqvist, E., Saxne, T., Geborek, P. (2007). Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66: 670-675 [Abstract] [Full Text]  
• Baron, G., Boutron, I., Giraudeau, B., Ravaud, P. (2007). Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. Ann Rheum Dis 66: 651-657 [Abstract] [Full Text]  
• Popa, C., Netea, M. G., van Riel, P. L. C. M., van der Meer, J. W. M., Stalenhoef, A. F. H. (2007). The role of TNF-{alpha} in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 48: 751-762 [Abstract] [Full Text]  
• Plater-Zyberk, C, Joosten, L A B, Helsen, M M A, Hepp, J, Baeuerle, P A, van den Berg, W B (2007). GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 66: 452-457 [Abstract] [Full Text]  
• O'Dell, J. R. (2007). The BeSt Way to Treat Early Rheumatoid Arthritis?. ANN INTERN MED 146: 459-460 [Full Text]  
• Itoh, Y., Hayashi, H., Miyazawa, K., Kojima, S., Akahoshi, T., Onozaki, K. (2007). 17beta-Estradiol Induces IL-1{alpha} Gene Expression in Rheumatoid Fibroblast-Like Synovial Cells through Estrogen Receptor {alpha} (ER{alpha}) and Augmentation of Transcriptional Activity of Sp1 by Dissociating Histone Deacetylase 2 from ER{alpha}. J. Immunol. 178: 3059-3066 [Abstract] [Full Text]  
• Kimura, M., Kawahito, Y., Obayashi, H., Ohta, M., Hara, H., Adachi, T., Tokunaga, D., Hojo, T., Hamaguchi, M., Omoto, A., Ishino, H., Wada, M., Kohno, M., Tsubouchi, Y., Yoshikawa, T. (2007). A Critical Role for Allograft Inflammatory Factor-1 in the Pathogenesis of Rheumatoid Arthritis. J. Immunol. 178: 3316-3322 [Abstract] [Full Text]  
• Maria Lizzio, M., Peluso, G., Zoli, A., Gremese, E., Tolusso, B., Ferraccioli, G. (2007). Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. Ann Rheum Dis 66: 427-428 [Full Text]  
• Flossmann, O., Bacon, P., de Groot, K., Jayne, D., Rasmussen, N., Seo, P., Westman, K., Luqmani, R. (2007). Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66: 283-292 [Abstract] [Full Text]  
• Bobbio-Pallavicini, F., Caporali, R., Alpini, C., Avalle, S., Epis, O. M, Klersy, C., Montecucco, C. (2007). High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis. Ann Rheum Dis 66: 302-307 [Abstract] [Full Text]  
• Biester, S., Deuter, C., Michels, H., Haefner, R., Kuemmerle-Deschner, J., Doycheva, D., Zierhut, M. (2007). Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91: 319-324 [Abstract] [Full Text]  
• Sakuma, M., Hatsushika, K., Koyama, K., Katoh, R., Ando, T., Watanabe, Y., Wako, M., Kanzaki, M., Takano, S., Sugiyama, H., Hamada, Y., Ogawa, H., Okumura, K., Nakao, A. (2007). TGF-{beta} type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol 19: 117-126 [Abstract] [Full Text]  
• van der Laken, C J, Voskuyl, A E, Roos, J C, Stigter van Walsum, M, de Groot, E R, Wolbink, G, Dijkmans, B A C, Aarden, L A (2007). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66: 253-256 [Abstract] [Full Text]  
• Russell, A S, Wallenstein, G V, Li, T, Martin, M C, Maclean, R, Blaisdell, B, Gajria, K, Cole, J C, Becker, J-C, Emery, P (2007). Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 66: 189-194 [Abstract] [Full Text]  
• Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., Dougados, M. (2007). Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46: 327-334 [Abstract] [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Combe, B, Landewe, R, Lukas, C, Bolosiu, H D, Breedveld, F, Dougados, M, Emery, P, Ferraccioli, G, Hazes, J M W, Klareskog, L, Machold, K, Martin-Mola, E, Nielsen, H, Silman, A, Smolen, J, Yazici, H (2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 34-45 [Abstract] [Full Text]  
• Yazici, Y, Yazici, H (2007). A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors. Ann Rheum Dis 66: 124-127 [Abstract] [Full Text]  
• Flendrie, M., Creemers, M. C. W., van Riel, P. L. C. M. (2007). Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 46: 146-149 [Abstract] [Full Text]  
• Gaffo, A., Saag, K. G., Curtis, J. R. (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465 [Abstract] [Full Text]  
• Dale, E., Davis, M., Faustman, D. L. (2006). A role for transcription factor NF-{kappa}B in autoimmunity: possible interactions of genes, sex, and the immune response. Adv. Physiol. Educ. 30: 152-158 [Abstract] [Full Text]  
• Fujio, K., Okamoto, A., Araki, Y., Shoda, H., Tahara, H., Tsuno, N. H., Takahashi, K., Kitamura, T., Yamamoto, K. (2006). Gene Therapy of Arthritis with TCR Isolated from the Inflamed Paw. J. Immunol. 177: 8140-8147 [Abstract] [Full Text]  
• Chung, C P, Thompson, J L, Koch, G G, Amara, I, Strand, V, Pincus, T (2006). Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis 65: 1602-1607 [Abstract] [Full Text]  
• van Kuijk, A W R, Reinders-Blankert, P, Smeets, T J M, Dijkmans, B A C, Tak, P P (2006). Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 65: 1551-1557 [Abstract] [Full Text]  
• Yamada, T, Nakajima, A, Inoue, E, Tanaka, E, Hara, M, Tomatsu, T, Kamatani, N, Yamanaka, H (2006). Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65: 1661-1663 [Abstract] [Full Text]  
• Hyrich, K. L., Watson, K. D., Silman, A. J., Symmons, D. P. M., The BSR Biologics Register, (2006). Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Westhovens, R., Cole, J. C., Li, T., Martin, M., MacLean, R., Lin, P., Blaisdell, B., Wallenstein, G. V., Aranda, R., Sherrer, Y. (2006). Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45: 1238-1246 [Abstract] [Full Text]  
• Huugen, D., Cohen Tervaert, J. W., Heeringa, P. (2006). TNF-{alpha} Bioactivity-Inhibiting Therapy in ANCA-Associated Vasculitis: Clinical and Experimental Considerations. CJASN 1: 1100-1107 [Abstract] [Full Text]  
• Scott, D.L., Kingsley, G.H. (2006). Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis.. NEJM 355: 704-712 [Full Text]  
• Fleischmann, R M, Tesser, J, Schiff, M H, Schechtman, J, Burmester, G-R, Bennett, R, Modafferi, D, Zhou, L, Bell, D, Appleton, B (2006). Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1006-1012 [Abstract] [Full Text]  
• Laas, K, Peltomaa, R, Kautiainen, H, Puolakka, K, Leirisalo-Repo, M (2006). Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 65: 924-928 [Abstract] [Full Text]  
• Schiff, M H, Burmester, G R, Kent, J D, Pangan, A L, Kupper, H, Fitzpatrick, S B, Donovan, C (2006). Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889-894 [Abstract] [Full Text]  
• Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E. M., Lipsky, P. E. (2006). TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108: 253-261 [Abstract] [Full Text]  
• Saika, S., Ikeda, K., Yamanaka, O., Flanders, K. C., Okada, Y., Miyamoto, T., Kitano, A., Ooshima, A., Nakajima, Y., Ohnishi, Y., Kao, W. W.-Y. (2006). Loss of Tumor Necrosis Factor {alpha} Potentiates Transforming Growth Factor {beta}-mediated Pathogenic Tissue Response during Wound Healing. Am. J. Pathol. 168: 1848-1860 [Abstract] [Full Text]